share_log

Truist Securities Reiterates Buy on Cytokinetics, Maintains $86 Price Target

Moomoo 24/7 ·  Apr 8 11:07

Truist Securities analyst Srikripa Devarakonda reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $86 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment